The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication. The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose mea

Global healthcare is a $12 trillion market carrying a 34-million worker shortage, yet healthtech captured just 5% of the $712 billion in global venture capital deployed in the first half of 2026. That gap, a trillion-dollar industry still treated as a rounding error by the venture industry, is the starting point for everything else here. We at Verge HealthTech Fund have always talked about how healthcare should transform from “sick-care” to “health + care.”

The Valuation Re-Frame: From Consumer Diet Drug to Sovereign Infrastructure Behind closed doors in institutional roundtables and private family office briefings, a fundamental valuation shift has occurred. The early narrative—dominated by direct-to-consumer weight-loss telehealth, consumer hype, and simple scale metrics—has run its course. Institutional allocators are now evaluating incretin receptor agonists through a far more rigorous lens: multi-systemic geroprotective pl

THE HORIZONS Dispatch | Oct - Nov 06 Mapping the future of healthspan capital, brainspan innovation, and luxury infrastructure across Europe, Asia, the Middle East, and beyond.

I spent years as a competitive athlete before any of this became my work, chasing personal bests the way this industry now chases biomarkers. My numbers, in the language of this field, were exceptional. And still, somewhere inside all that discipline, I hit a wall no training log could explain. I had never been fitter, and rarely felt less whole.

Direct macro intelligence synthesized from main-stage keynotes and private allocator dialogues at the seventh Longevity Investors Conference in Gstaad. What Top Allocators at the Longevity Investors Conference Are Quietly Rotating Out Of—and the Sovereign Infrastructure Replacing It.

Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion. Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.

On the Science, Art, and Soul of Wellness: Healthspan Evolution, Clinical Convergence, and the 20-Year Horizon

Cognitive sovereignty is the ultimate luxury in an era defined by algorithmic distraction. As elite performers seek to master the architecture of their attention, the brainspan—the depth and resilience of our focus—emerges as the definitive metric of success. Aware provides the infrastructure to reclaim this bandwidth, transforming the ear into a high-fidelity diagnostic portal for the modern executive.

At the convergence of geroscience venture capital, private equity roll-ups, and ultra-luxury urban development lies Age-in-Place Longevity Real Estate. By embedding non-invasive diagnostic arrays, adaptive universal design, and invisible healthspan tech directly into private fee-simple units—where average resident retention stretches to 12 to 18 years—these developments de-risk tenant turnover to near-zero churn, boost net operating income by 28% to 42% through high-margin he

Capital follows vitality. Here is where the global longevity, investment, and high-performance ecosystem meets next.

Discover how the Basel Area and Roche are institutionalizing longevity as an asset class through a CHF 1.4B pivot into predictive, human-centric infrastructure.

The brainspan is not a static biological ceiling; it is a dynamic landscape of neural plasticity that can be architected and optimized. In the pursuit of luxury longevity, the modern leader requires more than just passive tracking—they demand an interpretive engine that translates raw physiological data into the precise "language" of peak performance. Atlas represents the vanguard of this interpretive shift, moving us from merely measuring health to actively decoding the com

Sleep, Sweat, Scale: The Executive Routine Reimagined by Equinox Hotels Equinox Hotels is redefining luxury for high-performers—not with opulence, but with sleep, recovery, and performance-focused environments. From circadian-aligned rooms to 360-degree fitness labs and data-driven wellness rituals, these spaces support stamina, clarity, and sustainable scaling. High-performance hospitality isn’t indulgence—it’s infrastructure for success. Extending Horizons. Elevating Life

Under the light of Angsana Laguna Phuket, the atmosphere at BEING 2026 felt less like a standard industry gathering and more like a quiet turning point for regional capital. Co-curated by C9 Hotelworks and Delivering Asia, the summit stepped beyond familiar leisure rhetoric to confront a deeper reality unfolding across the island: the fundamental convergence of real estate, clinical medicine, and high-end hospitality.

The Evolution: From Private Diagnostic Labs to Public Arenas For years, the longevity narrative belonged almost exclusively to clinical diagnostics, pharmaceutical interventions, and quiet metabolic retreats. Millions were poured into measuring VO_2 max, muscle mass retention, and baseline cardiovascular health inside private labs. Then came Hyrox—and brought the diagnostics out of the clinic and into the arena.

Exploring Longevity Entrepreneurship, Innovation, and Executive Vitality Complementing this venture-building expertise, Marc is the architect behind the Longevity Investors Conference, the world’s premier private gathering at the intersection of longevity science and capital. While he hosts the exclusive "Longevity Investors Lunch" annually during the World Economic Forum in Davos—a critical platform for high-level dialogue—the flagship Longevity Investors Conference in Gstaa

How policy, urban design and prevention are reshaping the way a nation ages. When National Geographic Fellow Dan Buettner described Singapore as an "Engineered Blue Zone" in 2023, it challenged the long-held belief that exceptional health and longevity are largely the product of culture, geography or genetics. Singapore offers a different model. Its success has been shaped through deliberate policy, long-term planning and sustained investment in population

Anna Bjurstam is the founder of Wahayla, an independent global wellness and longevity advisory dedicated to advancing the convergence of biological optimization, luxury hospitality, and human experience. An internationally renowned thought leader and strategist, she advises hotel groups, fitness brands, and medical institutions on transitioning from transactional health services to enduring lifestyle ecosystems—reframing the value proposition of physical real estate around se

The metrics that have defined elite human performance for the past decade are quietly becoming baseline commodities. The global vanguard has spent years meticulously quantifying the vessel—mapping heart rate variability like financial charts, tracking sleep architecture, and measuring glycemic responses to environmental inputs. Yet, as the physical domain becomes increasingly optimized, a profound realization is taking root among those who operate at the absolute limits of pe